Immutep to present efti data at two international congresses
Immutep (ASX: IMM; NASDAQ: IMMP) announced that data from two clinical trials of its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), will be presented in poster presentations at two international congresses in November and December 2026.
The first is the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting in Seoul, South Korea, on 18-21 November 2026. The second is the ESMO Immuno-Oncology & Advanced Therapies Congress 2026 in London, United Kingdom, on 14-16 December 2026.
Both trials evaluate efti in combination with KEYTRUDA® (pembrolizumab). The data will be made available on the Posters & Publications page of Immutep’s website following each presentation.
When big ASX news breaks, our subscribers know first
CTOS 2026 to show EFTISARC-NEO survival data in soft tissue sarcoma
At CTOS 2026, survival data will be presented from the investigator-initiated EFTISARC-NEO Phase II trial (NCT06128863). The trial evaluates efti in combination with KEYTRUDA® and radiotherapy in the neoadjuvant treatment of patients with resectable soft tissue sarcoma.
The poster focuses on Disease Free Survival (DFS) and sits in the Poster Discussion (Session 6) category. The first author is Pawel Sobczuk, MD PhD, of the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland.
The trial is led by an independent investigator and covers a soft tissue sarcoma setting, a separate tumour type from the head and neck cancer studied in TACTI-003.
The sarcoma program also carries FDA Orphan Drug Designation, granted in April 2026, which brings potential seven-year market exclusivity, tax credits for clinical trial costs and fee exemptions if efti reaches approval.
ESMO IO 2026 to present final TACTI-003 Part B survival results
At the ESMO Immuno-Oncology & Advanced Therapies Congress 2026, final median overall survival results will be presented from Part B of the TACTI-003 Phase IIb trial (NCT04811027). The trial evaluates efti plus KEYTRUDA® in first-line recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients with a PD-L1 combined positive score (CPS) of less than 1.
The poster will be shown in the Poster Display session. The first author is Claus A. Kristensen, MD PhD, of Copenhagen University Hospital in Copenhagen, Denmark.
Educational: why overall survival and disease free survival matter
Overall survival measures how long patients live after starting a treatment. Disease free survival measures how long patients remain free of the disease after treatment.
PD-L1 CPS is a score describing PD-L1 levels in a tumour, and a score below 1 indicates a low level. Investors in clinical-stage biotechs often watch survival endpoints because they are used to judge whether a therapy is helping patients.
Immutep is a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, and a pioneer in therapeutics related to Lymphocyte Activation Gene-3 (LAG-3).
Presentation schedule and what happens next for Immutep
The schedule below follows the source wording.
- CTOS 2026 Annual Meeting, Seoul: 18-21 November 2026.
- EFTISARC-NEO poster session: 19 November 2026, 04:30 p.m. KST (06:30 p.m. AEDT). Presented by first author Pawel Sobczuk.
- ESMO Immuno-Oncology & Advanced Therapies Congress, London: 14-16 December 2026.
- TACTI-003 Part B poster session: 14 December 2026, 17:30 GMT (15 December 2026, 4:30am AEDT). Presented by first author Claus A. Kristensen.
- Data posted on the Posters & Publications page of Immutep’s website following each presentation.
Both trials sit within Immutep’s registration-directed development plans, which focus on first-line HNSCC and neoadjuvant soft tissue sarcoma after a manufacturing scale difference was identified as the likely cause of the TACTI-004 outcome.
| Congress | Trial | Location | Poster session (AEDT) | Focus |
|---|---|---|---|---|
| CTOS 2026 Annual Meeting | EFTISARC-NEO (Phase II; NCT06128863) | Seoul, South Korea | 19 November 2026, 06:30 p.m. | Disease Free Survival in resectable soft tissue sarcoma |
| ESMO Immuno-Oncology & Advanced Therapies Congress 2026 | TACTI-003 Part B (Phase II; NCT04811027) | London, United Kingdom | 15 December 2026, 4:30am | Final median overall survival in first-line recurrent or metastatic HNSCC, PD-L1 CPS below 1 |
Don’t Miss the Next Biotech Breakthrough
Join 20,000+ investors getting FREE breaking ASX news within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to receive healthcare and biotech alerts the moment market-moving news breaks, and stay ahead of the market.